贝达药业(300558.SZ)：国家药品监督管理局批准帕妥珠单抗注射液上市

Core Viewpoint - The article reports that BeiGene (300558.SZ) has received a drug registration certificate from the National Medical Products Administration (NMPA) for the launch of its biosimilar drug, Perjeta (pertuzumab injection), in collaboration with Hangzhou Bozhrui Biopharmaceutical Co., Ltd. [1] Group 1 - The NMPA has approved the market launch of the biosimilar pertuzumab injection, branded as Bezetin® [1] - Bezetin® is developed by Bozhrui Biopharmaceutical, a wholly-owned subsidiary of Zhejiang Bozhrui Biopharmaceutical Co., Ltd. [1] - The drug is indicated for the treatment of early-stage breast cancer and metastatic breast cancer [1]